(vianews) - shares of erytech pharma (cac 40: eryp.pa) fell by a staggering 15.75% in 5 sessions from €0.91 to €0.77 at 01:56 est on monday, after four sequential sessions in a row of losses. cac 40 is falling 1.78% to €7,187.27, following the last session's downward trend.
erytech pharma's last close was €0.77, 65.86% under its 52-week high of €2.26.
about erytech pharma
erytech pharma s.a., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in france and the united states. its lead product candidate is eryaspase, which is in phase 3 clinical development for the treatment of second-line pancreatic cancer, and in phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. the company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target methionine cancers. the company was incorporated in 2004 and is headquartered in lyon, france.
earnings per share
as for profitability, erytech pharma has a trailing twelve months eps of €-0.93.
volatility
erytech pharma's last week, last month's, and last quarter's current intraday variation average was a negative 1.95%, a positive 2.10%, and a positive 5.68%.
erytech pharma's highest amplitude of average volatility was 3.30% (last week), 7.31% (last month), and 5.68% (last quarter).
earnings before interest, taxes, depreciation, and amortization
erytech pharma's ebitda is 7.45.
revenue growth
year-on-year quarterly revenue growth declined by 58.5%, now sitting on 2.2m for the twelve trailing months.
more news about erytech pharma (eryp.pa).